Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 2/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498403 | 0.79 | — | — | |
| SCHEMBL9301268 | 0.78 | TP53 (0.35) | TP53 | |
| SCHEMBL8439081 | 0.72 | P2RX4 (0.33) | P2RX4P2RX1P2RX3P2RX7ALDH1A1 | |
| SCHEMBL10871210 | 0.72 | P2RX4 (0.33) | P2RX4P2RX1P2RX3P2RX7ALDH1A1 | |
| SCHEMBL497743 | 0.71 | TSHR (0.32) | ALDH1A1 | |
| SCHEMBL5826301 | 0.71 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL28497682 | 0.71 | CA1 (0.33) | P2RX4P2RX1P2RX3P2RX7 | |
| SCHEMBL498296 | 0.71 | — | — | |
| SCHEMBL82497 | 0.69 | TSHR (0.33) | P2RX4P2RX1P2RX3P2RX7ALDH1A1 | |
| SCHEMBL42466 | 0.69 | P2RX4 (0.32) | P2RX4P2RX1P2RX3P2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | claimed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | claimed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | claimed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| EP-1121372-B1 | ADENINE DERIVATIVES | PFIZER LTD (GB) | 2006-06-28 | — | — | EP | claimed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | claimed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | claimed |
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | claimed |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2024-03-26 | — | — | US | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-4169575-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667259-A | Condensed ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2022-02-24 | — | — | US | disclosed |
| US-4950648-A | SUBSTITUTED PYRIDO(2,3-D) OR PYRIMIDO(4,5-D) PYRIMIDINE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-08-21 | — | — | US | disclosed |
| EP-0192255-B1 | BIS-2H-PYRROLIDINE DIONES | CIBA-GEIGY AG (CH) | 1990-08-08 | — | — | EP | disclosed |
| EP-0316668-A2 | Use of a tetrahydro-pyrido(2,3-d)pyrimidine for obtaining an analgetic agent | MERCK PATENT GmbH (DE) | 1989-05-24 | — | — | EP | disclosed |
| US-4789674-A | ALZHEIMER'S DISEASE, MEMORY, DEMENTIA | CIBA-GEIGY CORPORATION (US) | 1988-12-06 | — | — | US | disclosed |
| US-4758575-A | Bi-2H-pyrroli(di)nediones | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0192255-A2 | Bis-2H-pyrrolidine diones | CIBA-GEIGY AG (CH) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | DHPS, SQLE, CYP51A1 | P2RX4 4561/4885P2RX1 4484/4885P2RX3 4545/4885 |
| US-20090023704-A1 | Novel Compounds 737 | GRPR, GABRB1, GABBR1 | P2RX4 67/4885P2RX1 41/4885P2RX3 57/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | P2RX4 2729/4885P2RX1 1787/4885P2RX3 2026/4885 |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | DHPS, SQLE, CYP51A1 | P2RX4 4561/4885P2RX1 4484/4885P2RX3 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.